842 related articles for article (PubMed ID: 20021434)
21. Increased expression of interleukin 17 in inflammatory bowel disease.
Fujino S; Andoh A; Bamba S; Ogawa A; Hata K; Araki Y; Bamba T; Fujiyama Y
Gut; 2003 Jan; 52(1):65-70. PubMed ID: 12477762
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-2 production in pediatric inflammatory bowel disease: evidence for dissimilar mononuclear cell function in Crohn's disease and ulcerative colitis.
Gurbindo C; Sabbah S; Menezes J; Justinich C; Marchand R; Seidman EG
J Pediatr Gastroenterol Nutr; 1993 Oct; 17(3):247-54. PubMed ID: 8271122
[TBL] [Abstract][Full Text] [Related]
23. Experimental immunomodulatory therapy of inflammatory bowel disease.
Schreiber S
Neth J Med; 1998 Dec; 53(6):S24-31. PubMed ID: 9883011
[TBL] [Abstract][Full Text] [Related]
24. Cytokine expression in gingival and intestinal tissues of patients with periodontitis and inflammatory bowel disease: An exploratory study.
Menegat JS; Lira-Junior R; Siqueira MA; Brito F; Carvalho AT; Fischer RG; Figueredo CM
Arch Oral Biol; 2016 Jun; 66():141-6. PubMed ID: 26946440
[TBL] [Abstract][Full Text] [Related]
25. Alterations of the mucosal immune system in inflammatory bowel disease.
MacDermott RP
J Gastroenterol; 1996 Dec; 31(6):907-16. PubMed ID: 9027661
[TBL] [Abstract][Full Text] [Related]
26. Glucocorticoid resistance in inflammatory bowel disease.
Farrell RJ; Kelleher D
J Endocrinol; 2003 Sep; 178(3):339-46. PubMed ID: 12967327
[TBL] [Abstract][Full Text] [Related]
27. Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells.
Bisping G; Lügering N; Lütke-Brintrup S; Pauels HG; Schürmann G; Domschke W; Kucharzik T
Clin Exp Immunol; 2001 Jan; 123(1):15-22. PubMed ID: 11167992
[TBL] [Abstract][Full Text] [Related]
28. Crossover Subsets of CD4
Li J; Ueno A; Iacucci M; Fort Gasia M; Jijon HB; Panaccione R; Kaplan GG; Beck PL; Luider J; Barkema HW; Qian J; Gui X; Ghosh S
Dig Dis Sci; 2017 Sep; 62(9):2357-2368. PubMed ID: 28573508
[TBL] [Abstract][Full Text] [Related]
29. IL-23 in inflammatory bowel diseases and colon cancer.
Neurath MF
Cytokine Growth Factor Rev; 2019 Feb; 45():1-8. PubMed ID: 30563755
[TBL] [Abstract][Full Text] [Related]
30. Study of tumor necrosis factor receptor in the inflammatory bowel disease.
Souza RF; Caetano MAF; Magalhães HIR; Castelucci P
World J Gastroenterol; 2023 May; 29(18):2733-2746. PubMed ID: 37274062
[TBL] [Abstract][Full Text] [Related]
31. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome.
Van Damme N; De Keyser F; Demetter P; Baeten D; Mielants H; Verbruggen G; Cuvelier C; Veys EM; De Vos M
Clin Exp Immunol; 2001 Sep; 125(3):383-90. PubMed ID: 11531945
[TBL] [Abstract][Full Text] [Related]
32. Cytokine production profile in intestinal mucosa of paediatric inflammatory bowel disease.
Vitale S; Strisciuglio C; Pisapia L; Miele E; Barba P; Vitale A; Cenni S; Bassi V; Maglio M; Del Pozzo G; Troncone R; Staiano A; Gianfrani C
PLoS One; 2017; 12(8):e0182313. PubMed ID: 28797042
[TBL] [Abstract][Full Text] [Related]
33. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases.
Serriari NE; Eoche M; Lamotte L; Lion J; Fumery M; Marcelo P; Chatelain D; Barre A; Nguyen-Khac E; Lantz O; Dupas JL; Treiner E
Clin Exp Immunol; 2014 May; 176(2):266-74. PubMed ID: 24450998
[TBL] [Abstract][Full Text] [Related]
34. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies.
Van Assche G; Vermeire S; Rutgeerts P
Gastroenterol Clin North Am; 2006 Dec; 35(4):743-56. PubMed ID: 17129811
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory bowel disease: new therapies from antisense oligonucleotides.
Marafini I; Monteleone G
Ann Med; 2018 Aug; 50(5):361-370. PubMed ID: 29911450
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
Catalan-Serra I; Brenna Ø
Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
[TBL] [Abstract][Full Text] [Related]
37. Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases.
De Nitto D; Sarra M; Cupi ML; Pallone F; Monteleone G
Curr Pharm Des; 2010; 16(33):3656-60. PubMed ID: 21128900
[TBL] [Abstract][Full Text] [Related]
38. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR).
Niessner M; Volk BA
Clin Exp Immunol; 1995 Sep; 101(3):428-35. PubMed ID: 7664489
[TBL] [Abstract][Full Text] [Related]
39. A Decade of Th9 Cells: Role of Th9 Cells in Inflammatory Bowel Disease.
Vyas SP; Goswami R
Front Immunol; 2018; 9():1139. PubMed ID: 29881387
[TBL] [Abstract][Full Text] [Related]
40. Chemokines in inflammatory bowel disease.
Papadakis KA
Curr Allergy Asthma Rep; 2004 Jan; 4(1):83-9. PubMed ID: 14680627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
